These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 27753185)

  • 1. Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer.
    Fernández MI; Williams SB; Willis DL; Slack RS; Dickstein RJ; Parikh S; Chiong E; Siefker-Radtke AO; Guo CC; Czerniak BA; McConkey DJ; Shah JB; Pisters LL; Grossman HB; Dinney CP; Kamat AM
    BJU Int; 2017 May; 119(5):684-691. PubMed ID: 27753185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes of cT1 micropapillary bladder cancer.
    Willis DL; Fernandez MI; Dickstein RJ; Parikh S; Shah JB; Pisters LL; Guo CC; Henderson S; Czerniak BA; Grossman HB; Dinney CP; Kamat AM
    J Urol; 2015 Apr; 193(4):1129-34. PubMed ID: 25254936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients.
    Kamat AM; Dinney CP; Gee JR; Grossman HB; Siefker-Radtke AO; Tamboli P; Detry MA; Robinson TL; Pisters LL
    Cancer; 2007 Jul; 110(1):62-7. PubMed ID: 17542024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer.
    Hermans TJN; Voskuilen CS; Deelen M; Mertens LS; Horenblas S; Meijer RP; Boormans JL; Aben KK; van der Heijden MS; Pos FJ; de Wit R; Beerepoot LV; Verhoeven RHA; van Rhijn BWG
    Int J Cancer; 2019 Mar; 144(6):1453-1459. PubMed ID: 30155893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of Patient Selection for Neoadjuvant Chemotherapy in Muscle-invasive Urothelial Carcinoma of the Bladder.
    Hensley PJ; Goodwin J; Davenport DL; Strup SE; James A
    Clin Genitourin Cancer; 2018 Aug; 16(4):e851-e858. PubMed ID: 29548614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis.
    Soria F; Black PC; Fairey AS; Cookson MS; Yu EY; Kassouf W; Dall'Era MA; Sridhar SS; McGrath JS; Wright JL; Thorpe AC; Morgan TM; Daneshmand S; Holzbeierlein JM; Bivalacqua TJ; North S; Barocas DA; Lotan Y; Grivas P; Stephenson AJ; Shah JB; van Rhijn BW; Spiess PE; Shariat SF; Gontero P
    BJU Int; 2021 Jul; 128(1):79-87. PubMed ID: 33152179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion.
    Metcalfe MJ; Ferguson JE; Li R; Xiao L; Guo CC; Czerniak BA; Siefker-Radtke A; Pretzsch SM; Navai N; McConkey DJ; Kamat AM; Campbell M; Dinney C
    Eur Urol Focus; 2017 Dec; 3(6):577-583. PubMed ID: 28753816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncologic Outcomes of cT1 and cT2 Micropapillary Variant Compared with cT1 and cT2 Conventional Urothelial Carcinoma Treated with Radical Cystectomy.
    Ginsburg KB; Schober JP; Bukavina L; Murray N; Chandra AA; Chen DYT; Greenberg RE; Viterbo R; Uzzo RG; Smaldone MC; Kutikov A; Correa AF
    Urol Pract; 2022 Sep; 9(5):396-404. PubMed ID: 37145732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of neoadjuvant chemotherapy on short-term complications and survival following radical cystectomy.
    Milenkovic U; Akand M; Moris L; Demaegd L; Muilwijk T; Bekhuis Y; Laenen A; Van Cleynenbreugel B; Everaerts W; Van Poppel H; Dumez H; Albersen M; Joniau S
    World J Urol; 2019 Sep; 37(9):1857-1866. PubMed ID: 30519746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis.
    Bhindi B; Frank I; Mason RJ; Tarrell RF; Thapa P; Cheville JC; Costello BA; Pagliaro LC; Karnes RJ; Thompson RH; Tollefson MK; Boorjian SA
    Eur Urol; 2017 Nov; 72(5):660-664. PubMed ID: 28545841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Natural History, Treatment Pattern, and Outcomes of Patients With Micropapillary Bladder Carcinoma.
    Wang J; Wang FW
    Am J Clin Oncol; 2015 Oct; 38(5):472-8. PubMed ID: 24064750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A risk-stratified approach to neoadjuvant chemotherapy in muscle-invasive bladder cancer: implications for patients classified with low-risk disease.
    Lyon TD; Frank I; Sharma V; Shah PH; Tollefson MK; Thompson RH; Karnes RJ; Thapa P; Cheville JC; Boorjian SA
    World J Urol; 2019 Aug; 37(8):1605-1613. PubMed ID: 30392012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology.
    Vetterlein MW; Wankowicz SAM; Seisen T; Lander R; Löppenberg B; Chun FK; Menon M; Sun M; Barletta JA; Choueiri TK; Bellmunt J; Trinh QD; Preston MA
    Cancer; 2017 Nov; 123(22):4346-4355. PubMed ID: 28743155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Squamous cell carcinoma of the bladder: poor response to neoadjuvant chemotherapy.
    Dotson A; May A; Davaro F; Raza SJ; Siddiqui S; Hamilton Z
    Int J Clin Oncol; 2019 Jun; 24(6):706-711. PubMed ID: 30707342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cystectomy vs. bladder preservation after neoadjuvant chemotherapy in muscle-invasive bladder cancer: A tertiary medical center experience.
    Halabi IE; Husseini ZE; Haibe Y; Charafeddine M; Mukherji D; Temraz S; Bulbul M; Khauli R; Nasr R; Wazzan W; Hajj AE; Geara F; Shamseddine A
    Cancer Treat Res Commun; 2020; 25():100222. PubMed ID: 33080450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A precystectomy decision model to predict pathological upstaging and oncological outcomes in clinical stage T2 bladder cancer.
    Mitra AP; Skinner EC; Miranda G; Daneshmand S
    BJU Int; 2013 Feb; 111(2):240-8. PubMed ID: 22928881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A delay ≥8 weeks to neoadjuvant chemotherapy before radical cystectomy increases the risk of upstaging.
    Audenet F; Sfakianos JP; Waingankar N; Ruel NH; Galsky MD; Yuh BE; Gin GE
    Urol Oncol; 2019 Feb; 37(2):116-122. PubMed ID: 30509868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of Preoperative Risk Grouping of the Selection of Patients Most Likely to Benefit From Neoadjuvant Chemotherapy Before Radical Cystectomy.
    Moschini M; Soria F; Klatte T; Wirth GJ; Özsoy M; Gust K; Briganti A; Roupret M; Susani M; Haitel A; Shariat SF
    Clin Genitourin Cancer; 2017 Apr; 15(2):e267-e273. PubMed ID: 27530435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy.
    Gondo T; Nakashima J; Ohno Y; Choichiro O; Horiguchi Y; Namiki K; Yoshioka K; Ohori M; Hatano T; Tachibana M
    Urology; 2012 May; 79(5):1085-91. PubMed ID: 22446338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidity.
    Johnson DC; Nielsen ME; Matthews J; Woods ME; Wallen EM; Pruthi RS; Milowsky MI; Smith AB
    BJU Int; 2014 Aug; 114(2):221-8. PubMed ID: 24274722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.